SQR PHARMA CONSULTING LTD Company accounts

SQR PHARMA CONSULTING LTD Company accounts

SQR PHARMA CONSULTING LTD - Company Information

Print Friendly Version

1 false false false true false false false false false false true false false false false false false 2021-01-01 Sage Accounts Production Advanced 2021 - FRS102_2021 70,486 25,928 44,558 44,558 xbrli:pure xbrli:shares iso4217:GBP 08901689 2021-01-01 2021-12-31 08901689 2021-12-31 08901689 2020-01-01 2020-12-31 08901689 2020-12-31 08901689 core:Subsidiary1 2021-01-01 2021-12-31 08901689 core:PlantMachinery 2021-01-01 2021-12-31 08901689 bus:Director1 2021-01-01 2021-12-31 08901689 bus:Director2 2021-01-01 2021-12-31 08901689 bus:Director4 2021-01-01 2021-12-31 08901689 bus:Director5 2021-01-01 2021-12-31 08901689 bus:Director5 2021-12-31 08901689 core:WithinOneYear 2021-12-31 08901689 core:WithinOneYear 2020-12-31 08901689 core:PlantMachinery 2021-12-31 08901689 core:ShareCapital 2020-01-01 2020-12-31 08901689 core:OtherReservesSubtotal 2020-01-01 2020-12-31 08901689 core:RetainedEarningsAccumulatedLosses 2020-01-01 2020-12-31 08901689 core:ShareCapital 2021-01-01 2021-12-31 08901689 core:OtherReservesSubtotal 2021-01-01 2021-12-31 08901689 core:RetainedEarningsAccumulatedLosses 2021-01-01 2021-12-31 08901689 core:ShareCapital 2021-12-31 08901689 core:ShareCapital 2020-12-31 08901689 core:OtherReservesSubtotal 2021-12-31 08901689 core:OtherReservesSubtotal 2020-12-31 08901689 core:RetainedEarningsAccumulatedLosses 2021-12-31 08901689 core:RetainedEarningsAccumulatedLosses 2020-12-31 08901689 core:RetainedEarningsAccumulatedLosses 2019-12-31 08901689 core:RestatedAmount 2019-12-31 08901689 core:RestatedAmount 2020-12-31 08901689 core:CostValuation core:Non-currentFinancialInstruments 2021-12-31 08901689 core:Non-currentFinancialInstruments 2021-12-31 08901689 core:Non-currentFinancialInstruments 2020-12-31 08901689 core:PlantMachinery 2020-12-31 08901689 bus:SmallEntities 2021-01-01 2021-12-31 08901689 bus:AuditExempt-NoAccountantsReport 2021-01-01 2021-12-31 08901689 bus:FullAccounts 2021-01-01 2021-12-31 08901689 bus:SmallCompaniesRegimeForAccounts 2021-01-01 2021-12-31 08901689 bus:PrivateLimitedCompanyLtd 2021-01-01 2021-12-31
COMPANY REGISTRATION NUMBER: 08901689
SQR PHARMA CONSULTING LTD
Unaudited Financial Statements
31 December 2021
SQR PHARMA CONSULTING LTD
Financial Statements
Year ended 31 December 2021
Contents
Page
Directors' report
1
Income statement
2
Statement of financial position
3
Statement of changes in equity
5
Notes to the financial statements
6
SQR PHARMA CONSULTING LTD
Directors' Report
Year ended 31 December 2021
The directors present their report and the unaudited financial statements of the company for the year ended 31 December 2021 .
Principal activities
The principal activity of the company during the year was that of a wholesaler of pharmaceutical goods.
Directors
The directors who served the company during the year were as follows:
Mr Angelo Priore
Mr Alfonso Sciotti
Mr Ilya Zaltsaman
Mrs Mavlyuda Mirzakhanova
(Appointed 25 January 2021)
Small company provisions
This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.
This report was approved by the board of directors on 8 August 2022 and signed on behalf of the board by:
Mr Angelo Priore
Mr Alfonso Sciotti
Director
Director
Mr Ilya Zaltsaman
Mrs Mavlyuda Mirzakhanova
Director
Director
SQR PHARMA CONSULTING LTD
Income Statement
Year ended 31 December 2021
2021
2020
Note
£
£
Turnover
4
4,535,483
3,731,322
Cost of sales
( 2,984,635)
( 2,509,458)
------------
------------
Gross profit
1,550,848
1,221,864
Administrative expenses
( 775,302)
( 286,744)
------------
------------
Operating profit
775,546
935,120
Interest payable and similar expenses
–
( 52)
------------
------------
Profit before taxation
6
775,546
935,068
Tax on profit
( 179,273)
( 185,360)
---------
---------
Profit for the financial year
596,273
749,708
---------
---------
All the activities of the company are from continuing operations.
SQR PHARMA CONSULTING LTD
Statement of Financial Position
31 December 2021
2021
2020
Note
£
£
Fixed assets
Tangible assets
7
44,558
44,558
Investments
8
712,594
737,741
---------
---------
757,152
782,299
Current assets
Debtors
9
1,344,580
1,803,094
Cash at bank and in hand
5,280,723
4,527,053
------------
------------
6,625,303
6,330,147
Creditors: amounts falling due within one year
10
3,416,551
1,709,051
------------
------------
Net current assets
3,208,752
4,621,096
------------
------------
Total assets less current liabilities
3,965,904
5,403,395
------------
------------
Net assets
3,965,904
5,403,395
------------
------------
Capital and reserves
Called up share capital
170,000
200,000
Merge reserve
2,568,655
2,614,297
Profit and loss account
1,227,249
2,589,098
------------
------------
Shareholders funds
3,965,904
5,403,395
------------
------------
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
For the year ending 31 December 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
SQR PHARMA CONSULTING LTD
Statement of Financial Position (continued)
31 December 2021
These financial statements were approved by the board of directors and authorised for issue on 8 August 2022 , and are signed on behalf of the board by:
Mr Angelo Priore
Mr Alfonso Sciotti
Director
Director
Mr Ilya Zaltsaman
Mrs Mavlyuda Mirzakhanova
Director
Director
Company registration number: 08901689
SQR PHARMA CONSULTING LTD
Statement of Changes in Equity
Year ended 31 December 2021
Called up share capital
Merge reserve
Profit and loss account
Total
£
£
£
£
At 1 January 2020
–
–
1,863,477
1,863,477
Profit for the year
749,708
749,708
Other comprehensive income for the year:
Movement of the year
–
2,614,297
–
2,614,297
----
------------
------------
------------
Total comprehensive income for the year
–
2,614,297
749,708
3,364,005
Issue of shares
200,000
–
–
200,000
Dividends paid and payable
–
–
( 24,087)
( 24,087)
---------
------------
------------
------------
Total investments by and distributions to owners
200,000
–
( 24,087)
175,913
At 31 December 2020
200,000
2,614,297
2,589,098
5,403,395
Profit for the year
596,273
596,273
Other comprehensive income for the year:
Movement of the year
–
(45,642)
–
(45,642)
---------
------------
------------
------------
Total comprehensive income for the year
–
( 45,642)
596,273
550,631
Dividends paid and payable
–
–
( 1,958,122)
( 1,958,122)
Redemption of shares
( 30,000)
–
–
( 30,000)
--------
----
------------
------------
Total investments by and distributions to owners
( 30,000)
–
( 1,958,122)
( 1,988,122)
---------
------------
------------
------------
At 31 December 2021
170,000
2,568,655
1,227,249
3,965,904
---------
------------
------------
------------
SQR PHARMA CONSULTING LTD
Notes to the Financial Statements
Year ended 31 December 2021
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Unit 502 30 Great Guildford Street, London, SE1 0HS, United Kingdom.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Foreign currencies
Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Plant and machinery
-
20% straight line
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Investments in associates
Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Investments in joint ventures
Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.
4. Turnover
The whole of the turnover is attributable to the principal activity of the company wholly undertaken in the United Kingdom.
5. Employee numbers
The average number of persons employed by the company during the year amounted to 1 (2020: 1 ).
6. Profit before taxation
Profit before taxation is stated after charging:
2021
2020
£
£
Depreciation of tangible assets
–
11,140
----
--------
7. Tangible assets
Plant and machinery
£
Cost
At 1 January 2021 and 31 December 2021
70,486
--------
Depreciation
At 1 January 2021 and 31 December 2021
25,928
--------
Carrying amount
At 31 December 2021
44,558
--------
At 31 December 2020
44,558
--------
8. Investments
Shares in group undertakings
Loans to participating interests
Total
£
£
£
Cost
At 1 January 2021 and 31 December 2021
431,456
281,138
712,594
---------
---------
---------
Impairment
At 1 January 2021 and 31 December 2021
–
–
–
---------
---------
---------
Carrying amount
At 31 December 2021
431,456
281,138
712,594
---------
---------
---------
At 31 December 2020
431,456
281,138
712,594
---------
---------
---------
Subsidiaries, associates and other investments
Class of share
Percentage of shares held
Subsidiary undertakings
Medlac s.r.l.
Ordinary
30
9. Debtors
2021
2020
£
£
Trade debtors
1,206,547
1,732,586
Prepayments and accrued income
22,706
66,537
Other debtors
115,327
3,971
------------
------------
1,344,580
1,803,094
------------
------------
10. Creditors: amounts falling due within one year
2021
2020
£
£
Trade creditors
1,319,266
1,439,397
Accruals and deferred income
3,525
74,034
Corporation tax
179,273
185,360
Social security and other taxes
1,225
475
Director loan accounts
–
237
Other creditors
1,612,812
–
Other creditors
300,450
9,548
------------
------------
3,416,551
1,709,051
------------
------------